Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01258998 · OUTCOME

Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · Source last updated 2020-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 30 days

What was measured

Toxicity data will be summarized by frequency tables.

Groups in this outcome

Akt Inhibitor MK2206

Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Akt Inhibitor MK220659

Reported measurements

Fatigue
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220612Not reportedNot reportedNot reportedNot reported
Anorexia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Aspartate aminotransferase elevation
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Constipation
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22063Not reportedNot reportedNot reportedNot reported
Diarrhea
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Nausea
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22069Not reportedNot reportedNot reportedNot reported
Hyperglycemia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220634Not reportedNot reportedNot reportedNot reported
Elevated creatinine
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Conjunctivitis
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Rash
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220631Not reportedNot reportedNot reportedNot reported
Dry skin
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22064Not reportedNot reportedNot reportedNot reported
Pruritus
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22066Not reportedNot reportedNot reportedNot reported
Anemia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK22065Not reportedNot reportedNot reportedNot reported
Thrombocytopenia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220615Not reportedNot reportedNot reportedNot reported
Neutropenia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220610Not reportedNot reportedNot reportedNot reported
Lymphopenia
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Akt Inhibitor MK220613Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    Fatigue
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Anorexia
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Aspartate aminotransferase elevation
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Constipation
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Diarrhea
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        9
    title
    Nausea
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        34
    title
    Hyperglycemia
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Elevated creatinine
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Conjunctivitis
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        31
    title
    Rash
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Dry skin
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Pruritus
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Toxicity data will be summarized by frequency tables.
groups
  1. description
    Akt inhibitor MK2206 200 mg orally once a week, repeats every 28 days for up to 12 courses.
    id
    OG000
    title
    Akt Inhibitor MK2206
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 30 days
title
Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice